A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. - Wikidata - awgldk - TriplyDB

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

http://www.wikidata.org/entity/Q34085379

about

Chapter 7: Pharmacogenomics Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Warfarin pharmacogenetics: does more accurate dosing benefit patients?Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.Population diversity and the performance of warfarin dosing algorithms.Pharmacogenomics: application to the management of cardiovascular disease Fibulin-1C, C1 Esterase Inhibitor and Glucose Regulated Protein 75 Interact with the CREC Proteins, Calumenin and Reticulocalbin.Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU Race influences warfarin dose changes associated with genetic factors.Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.The future of warfarin pharmacogenetics in under-represented minority groups.Pharmacogenomics of warfarin in populations of African descent.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.Role of pharmacogenomics in the management of traditional and novel oral anticoagulants Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement Pharmacoeconomic evaluation of warfarin pharmacogenomics.A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like1.Genotype-guided coumarin dosing: where are we now and where do we need to go next?Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.Warfarin Pharmacogenomics in Diverse Populations.Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity.Genetic determinants of variability in warfarin response after the dose-titration phase.The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing.VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.Gamma-glutamyl carboxylase and its influence on warfarin dose.Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.

P2860

Q21563496-C3B69BB8-753B-41F0-B965-6669DE21EF80 Q26823542-708E5B82-E7E2-43E7-BB2D-3FD76A6DE0EC Q27027304-FD056586-11CA-427C-9FF2-75CCEAAD8698 Q31016306-CC542411-2EEC-484C-A6C7-7B130254758E Q33591111-8D40C003-39AC-40B3-99F2-84F8A31CB2AB Q34050936-AC3F42E9-8D71-44D5-B60A-243A1AC68372 Q34284362-2E5431FE-3917-4CF9-9612-690D385B660D Q34571746-5F1FABA6-638B-455A-9B73-411778C23B7F Q34791041-AE027660-2641-40EB-BEC9-EFBAB4D2E6A0 Q35219658-158972FF-F7C2-434C-9994-6EE07D44A0D3 Q35309161-D08CAE88-A650-4019-97A0-B78A82736072 Q35687799-AD63E62D-5E14-4BE1-B11E-BBF10EDAAA41 Q35795982-83F41723-F4C0-4CFB-9A74-B564C2834CDB Q35884265-32CAA432-8D00-4C4C-8A8C-9AD4C8613762 Q35991881-57ED44E9-91EE-41FF-8CA7-C0146E266894 Q36228428-02C9692C-86D8-4960-A3B1-B02EDB372D1E Q36294461-1EBD589D-6FC0-4C27-A015-FC0BDF5BF829 Q36629209-542EA6BE-795B-45B2-A82D-7BCF8146962E Q36630081-C87825CB-8EEE-484C-94FC-5F151223B60F Q36717256-69CCB534-DCB4-4C2D-85D4-DEE62E7F167E Q36848449-6DAC9A33-4E2B-4B2B-B3FB-E0837F366282 Q36954725-D6EE4EF7-8170-4CBE-A7AC-D54AE6011FE1 Q37138272-D0133EEE-06A6-44C1-9717-66F0F2587AA9 Q37606335-71F57717-F74F-449D-B1D2-67C9307C8C5B Q37828165-093D4AD7-0281-4E5C-8854-2887B8FDDA42 Q37908891-024ECAD0-51D6-47C6-A53D-91A078D1010A Q38078754-091AC23A-46D0-48A3-85C6-72608B2F8E5C Q38103055-D4218A35-6C89-42B3-B93D-432BB92DAA6D Q38321269-1DBB275B-1A75-4EFC-A24A-4EC28479CA0D Q38496232-A3771843-9327-414F-A4BB-0FA38A69C32A Q38696567-87768B02-83AB-4D6B-B43B-6CF90017BFC8 Q38983845-BC718E8E-A8AB-4F3B-9812-8B3D76D82578 Q39053849-3A65B9E8-D5D6-4205-A253-21776EC7A38B Q42245258-2C4F9D2E-1FEE-460E-ADFD-5B73AE9FB2FD Q43113299-69C3840B-B97C-4D46-8634-D58C70A60284 Q44498037-DAF8F4BF-CCDF-48DD-B2B5-0CB24434C590 Q47345423-0A446969-6569-4A3E-AC28-B5388472ED5E Q47982335-2D6310AA-F652-4052-9C4A-F578351ADA33 Q49811574-67AD62AA-E5CD-42DE-AEEC-0915ED9AE4F8 Q50849656-0ABD384D-B258-4559-848E-4A91CD259ECB

P2860

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

http://www.wikidata.org/entity/Q34085379

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

A polymorphism in the VKORC1 r ...... irements in African Americans.

@ast

A polymorphism in the VKORC1 r ...... irements in African Americans.

@en

A polymorphism in the VKORC1 r ...... irements in African Americans.

@nl

type

label

A polymorphism in the VKORC1 r ...... irements in African Americans.

@ast

A polymorphism in the VKORC1 r ...... irements in African Americans.

@en

A polymorphism in the VKORC1 r ...... irements in African Americans.

@nl

prefLabel

A polymorphism in the VKORC1 r ...... irements in African Americans.

@ast

A polymorphism in the VKORC1 r ...... irements in African Americans.

@en

A polymorphism in the VKORC1 r ...... irements in African Americans.

@nl

P1433

Q34085379-4DE3E0FC-A4B2-47F1-8999-0E3FB56182FD

P1476

Q34085379-300DBE69-92BB-43FF-BCF9-A5E521B661A0

P2093

Q34085379-0CFA3AB9-93D3-4A46-ABE8-EA943B323EB8

Q34085379-21035455-AB91-4779-B698-1CEA1A32076A

Q34085379-27DFD531-3024-4DD2-9F04-F0F52AD00E36

Q34085379-2E961CDA-1989-4D49-BEDA-F2FAE5920A9B

Q34085379-3BC7863B-7A0A-4FC6-A959-E52E7EDDDEAA

Q34085379-3FB85BAB-A4E3-4D45-84DD-12472B613E4A

Q34085379-42E99F6D-4A67-4F3C-B06B-013BBC523D45

Q34085379-541F5AFA-C20C-4076-B24F-A522F6EA5008

Q34085379-57E7C784-04FD-4A31-96BC-D7D92AE32C04

Q34085379-5C2F301A-1117-45FF-9E21-008D5CA21281

P2860

Q34085379-014E3A33-236D-4414-93C3-04589BA9E0FB

Q34085379-08D75302-8EDE-42FE-95F4-E52826CA6BA7

Q34085379-0F478D6B-DB91-4C16-9B93-F459BD0EA708

Q34085379-299A8B76-6151-4DF7-91FA-7AFE0DF4B3AC

Q34085379-2AC4AA1D-AF3B-4205-975C-704BFD683DFA

Q34085379-2E848F61-8DD2-4A26-A20F-ED1A2C26EBB5

Q34085379-2EC79079-D440-4B7A-9DA5-2503D127C9F0

Q34085379-32A4A079-F922-499D-9019-94547934C701

Q34085379-36EA295D-D447-4F57-B62C-F839428F1D00

Q34085379-3C55ECFC-80A4-44E5-B3D9-6F90376B9F95

P2888

Q34085379-2B02C594-021E-45E0-B9F4-0899877F4E4B

P304

Q34085379-75C1ABE7-B780-418D-997E-50DF04635657

P31

Q34085379-50D86271-A361-4540-92DC-9DDECBE37307

P356

Q34085379-7B9F9FAC-1CA6-4FFC-AFC8-30AFAE1C3A29

P407

Q34085379-B67CCF1C-929F-41F7-A566-27D2304A1F8F

P433

Q34085379-575C2E58-2EE2-42FB-8B6B-551E75F8EAF2

P478

Q34085379-1B8AD781-640D-485B-A06D-D7365D7738C4

P577

Q34085379-B79AF443-6267-4E7A-B1BE-D85E60141929

P5875

Q34085379-9E573C0F-CB2F-463A-A545-03DC71B3F78F

P6179

Q34085379-3C02078E-C0F1-4290-952B-98EC0FA478E0

P698

Q34085379-D2C55FED-BA68-47D6-A72A-B33120F2F228

P932

Q34085379-25BA65BE-8B6D-403B-9983-32E507B3C7A9

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

A polymorphism in the VKORC1 r ...... irements in African Americans.

@en

P2093

B F Gage

http://www.w3.org/2001/XMLSchema#string

C R King

http://www.w3.org/2001/XMLSchema#string

C S Eby

http://www.w3.org/2001/XMLSchema#string

D C Koboldt

http://www.w3.org/2001/XMLSchema#string

D Voora

http://www.w3.org/2001/XMLSchema#string

E Deych

http://www.w3.org/2001/XMLSchema#string

G R Grice

http://www.w3.org/2001/XMLSchema#string

H L McLeod

http://www.w3.org/2001/XMLSchema#string

L H Cavallari

http://www.w3.org/2001/XMLSchema#string

M Crankshaw

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol

WGAViewer: software for genomic annotation of whole genome association studies

Haploview: analysis and visualization of LD and haplotype maps

Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal

The vitamin K-dependent carboxylase

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Molecular cloning of a cDNA encoding human calumenin, expression in Escherichia coli and analysis of its Ca2+-binding activity

A sequencing method based on real-time pyrophosphate

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

P2888

P304

445-451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2009.291

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41722325

http://www.w3.org/2001/XMLSchema#string

P6179

1002780027

http://www.w3.org/2001/XMLSchema#string

P698

20200517

http://www.w3.org/2001/XMLSchema#string

P932

2928561

http://www.w3.org/2001/XMLSchema#string